Lebenthal Global Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Lebenthal Global Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,669	Closed	-$212K	–	140
2022 Q2	$212K	Buy	2,669 +147	+6%	+$13.9K	0.1%	124
2022 Q1	$265K	Buy	2,522 +185	+8%	+$18K	0.11%	121
2021 Q4	$251K	Buy	+2,337	New	+$255K	0.1%	145
2021 Q1	–	Sell	-1,086	Closed	-$79K	–	592
2020 Q4	$79K	Buy	+1,086	New	+$80.7K	0.06%	200

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Lebenthal Global Advisors's HZNP Position: Q3 2022 in Review

Lebenthal Global Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 2,669 shares — an estimated $212K sold.

Lebenthal Global Advisors first reported a position in HZNP in Q4 2020 and held it in 4 quarters. The position peaked at $265K in Q1 2022. 530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

Lebenthal Global Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
Lebenthal Global Advisors sold 2,669 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $212K.
Lebenthal Global Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2020 and held it in 4 quarters.
Lebenthal Global Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $265K in Q1 2022.
530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Lebenthal Global Advisors's 13F filing for Q3 2022, filed 8 Nov 2022.